Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
复制标题
DOI：
10.3892/or.2013.2261
复制
发表时间：
2013-04-01
期刊：
影响因子：
4.2
通讯作者：
Wingren, Sten
中科院分区：
文献类型：
--
作者：
Eremo, Anna Gothlin;Wegman, Pia;Wingren, Sten
Wwox表达的减少或缺失最近与乳腺癌的他莫昔芬耐药有关，也被认为是治疗的候选预测指标。我们的目的是通过检查912名随机乳腺癌患者的组织来研究Wwox表达与他莫昔芬治疗结果的相关性。将患者肿瘤石蜡包埋组织置于组织芯片上，免疫组织化学染色Wwox蛋白。镜检后，采用Cox回归、Kaplan-Meier生存曲线和log-rank检验对结果进行分析。在没有Wwox表达的肿瘤组中，治疗组和未治疗组的无复发生存率无差异（P=0.81）。对于肿瘤表达中度或强Wwox蛋白的治疗病例，无复发生存率提高（P=0.001和P=0.003分别）。Wwox与治疗反应之间相互作用的测试表明，中度或强烈Wwox表达的治疗患者复发风险降低（HR=0.31, 95% CI 0.10-0.98， HR=0.28, 95% CI 0.08-0.97）。我们的研究结果表明，高表达Wwox的患者可能从他莫昔芬治疗中获得更多的益处。
Reduced or absent Wwox expression has recently been associated with tamoxifen resistance in breast cancer and has also been proposed as a candidate predictive marker for treatment. We aimed to investigate the correlation of Wwox expression with the outcome of tamoxifen treatment by examining tissues from 912 randomized breast cancer patients. Paraffin-embedded tissues from patient tumors were arranged on tissue microarray, and Wwox protein was stained using immunohistochemistry. After microscopic examination, the results were analyzed with Cox regression, Kaplan-Meier survival curves and the log-rank test. In the group of cases having a tumor absent for Wwox expression, there was no difference in recurrence-free survival between treated and untreated patients (P=0.81). For treated cases with a tumor expressing moderate or strong Wwox protein, recurrence-free survival was improved (P=0.001 and P=0.003, respectively). The test for interaction between Wwox and treatment response demonstrated a decreased risk of recurrence for treated patients with a moderate or strong Wwox expression (HR=0.31, 95% CI 0.10-0.98 and HR=0.28, 95% CI 0.08-0.97, respectively). Our results indicate that patients with high expression of Wwox may gain more benefit from treatment with tamoxifen.